Year: 2021
Type: review
Abstract: Epilepsy is a common and serious neurological disorder characterised by recurrent spontaneous seizures. Frontline pharmacotherapy includes small-molecule antiseizure drugs that typically target ion channels and neurotransmitter systems, but these fail in 30% of patients and do not prevent either the development or progression of epilepsy. An emerging therapeutic target is microRNA (miRNA), small noncoding RNAs that negatively regulate sets of proteins. Their multitargeting action offers unique advantages for certain forms of epilepsy with complex underlying pathophysiology, such as temporal lobe epilepsy (TLE). miRNA can be inhibited by designed antisense oligonucleotides (ASOs; e.g., antimiRs). Here, we outline the prospects for miRNA-based therapies. We review design considerations for nucleic acid-based approaches and the challenges and next steps in developing therapeutic miRNA-targeting molecules for epilepsy.
Authors: Gareth Morris, Denis O’Brien, David C. Henshall
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $6,700
Awards: G1311090270, G177484282, G2189472788, G2628364946, G265847165, G285994706, G3185061454, G3207356259, G3345895242, G393177772, G4689608210, G4937468798, G496129201, G5031057893, G5237714278, G5254896286, G5702163051, MicroRNA biofluid profiles as molecular diagnostics for epilepsy, Using human tissue to translate microRNA-based therapies for epilepsy, FutureNeuro, G6329715174, G6509606559, G7128578356, G8156542052, G836282752, MicroRNAs in the Pathogenesis, Treatment and Prevention of Epilepsy, G8512683158
OpenAlex ID: W3161295651